Table 3 HU-related treatment patterns associated with patients who discontinued and those who did not
Currently using HU therapy (n = 1080) | Discontinued HU therapy (n = 229) | |
|---|---|---|
Years diagnosed with PV | ||
n | 1080 | 229 |
Mean ± SD | 5.23 ± 2.77 | 5.25 ± 2.82 |
Duration of HU therapy for current users, mo | ||
n | 1080 | – |
Mean ± SD | 46.97 ± 30.83 | – |
Duration of HU therapy before discontinuation, mo | ||
n | – | 229 |
Mean ± SD | – | 23.19 ± 24.45 |
Current HU dose, mg/d | ||
n | 1055 | – |
Mean ± SD | 984.2 ± 673.6 | – |
Median (q25–q75) | 1000.0 (500.0–1000.0) | – |
Last dose of HU before discontinuation, mg/d | ||
n | – | 225 |
Mean ± SD | – | 990.9 ± 689.3 |
Median (q25–q75) | – | 1000.0 (500.0–1200.0) |
Highest ever HU dose, mg/d | ||
n | 491 | 123 |
Mean ± SD | 1413.0 ± 875.5 | 1443.6 ± 876.4 |
Median (q25–q75) | 1000.0 (1000.0–2000.0) | 1000.0 (1000.0–2000.0) |
Lowest ever HU dose, mg/d | ||
n | 503 | 125 |
Mean ± SD | 745.1 ± 576.8 | 744.0 ± 437.9 |
Median (q25–q75) | 500.0 (500.0–1000.0) | 500.0 (500.0–1000.0) |
Most stable HU dose, mg/d | ||
n | 468 | 114 |
Mean ± SD | 1129.8 ± 742.2 | 1167.2 ± 781.7 |
Median (q25–q75) | 1000.0 (712.5–1500.0) | 1000.0 (500.0–1500.0) |
Number of HU dose adjustments in 3 mo before discontinuation | ||
n | – | 205 |
Mean ± SD | – | 0.48 ± 1.06 |